N/A N=250 A Culturally Sensitive Intervention for TBI Caregivers in Latin America
Traumatic Brain Injury
Primary: Zarit Burden Interview — 23.41; 26.48 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,100 Phase III Study Comparing Efficacy and Safety of AFOLIA vs Gonal-f® RFF in Women (35 to 42) Undergoing IVF
Infertility
Primary: Clinical Pregnancy Rate After One Cycle of Treatment - ITT Population — 114; 138; 435; 413 Participants
N/A N=6 Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study
Idiopathic Guttate Hypomelanosis
Primary: Efficacy Outcome — 2.31; 1.15 units on a scale
Phase 4 N=60 ADASUVE 2-dose Thorough QT/QTc Study
Healthy Volunteers
Primary: Maximum Effect of ADASUVE on Cardiac Repolarization (QTc Interval Duration) at the Maximum Clinical Dose Compared to Placebo — 4.04 msec
Phase 2 N=22 Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Diffuse Large B-Cell Lymphoma
Primary: Number of Patients With a Complete Response — 7 Participants
Phase 3 N=530 DHEA Against Vaginal Atrophy - Safety Study of 12 Months
Vaginal Atrophy
Primary: Long-term Safety of Intravaginal Prasterone (DHEA): Endometrium — 421; 36 Participants
Phase 2 N=14 Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
Recurrent Melanoma · Stage IV Skin Melanoma
Primary: Overall Objective Response — 3; 3; 6 Participants
Phase 2 N=77 SB-681323 IV for Subjects at Risk of Acute Lung Injury or ARDS
Lung Injury, Acute
Primary: Mean Hematology Parameters Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, White Blood Cell Count — 0.0305; 0.0163; 0.0208; 0.0153…
Phase 3 N=740 Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis
Primary: Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16 — 12.4; 38.7; 39.2…
Phase 2 N=20 The Discriminative Effects of Tramadol in Humans
Opioid Abuse · Opioid Addiction · Stimulant Abuse
Primary: Acquisition of Discrimination Assessed by Accuracy of the Discrimination Test — 87; 87.5; 90 percent of correct response
Phase 3 N=489 Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)
Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 94.2 percentage of participants — p=<0.001
Phase 2 N=61 Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
Stage III Vulvar Cancer · Stage IVB Vulvar Cancer · Vulvar Squamous Cell Carcinoma
Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants
Phase 3 N=165 SMART-SF Radiofrequency Ablation Safety Study
Atrial Fibrillation
Primary: Percentage of Participants With Early Onset Primary Adverse Events — 2.6 Percentage of participants
N/A N=36 Neural Mechanisms of Change During the Treatment of Alcohol Use Disorders With Prazosin
Alcohol Use Disorder
Primary: Number of Standard Alcoholic Drinks Consumed Per Week (Drinks Per Week) — 13.65; 14.55; 15.11; 11.11 drinks per week
Phase 3 N=220 Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy
Asthma
Primary: Percentage Reduction in Final OCS Dose Compared With Baseline While Maintaining Asthma Control — 75.00; 75.00; 25.00 Percent — p=<0.001